Cargando…

A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes

Background: First dose observation for cardiac effects is required for fingolimod. Previous results in patients with relapsing remitting multiple sclerosis (RRMS) suggest that transient bradycardia and conduction abnormalities during the observation phase are rare, benign and reversible. Prior analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Limmroth, Volker, Ziemssen, Tjalf, Kleiter, Ingo, Wagner, Bert, Schmidt, Stephan, Lassek, Christoph, Baier-Ebert, Monika, Wendt, Guillaume, Dechend, Ralf, Haverkamp, Wilhelm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434833/ https://www.ncbi.nlm.nih.gov/pubmed/32903376 http://dx.doi.org/10.3389/fneur.2020.00818

Ejemplares similares

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study
por: Limmroth, Volker, et al.
Publicado: (2017)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Fingolimod for Irradiation-Induced Neurodegeneration
por: Metzdorf, Judith, et al.
Publicado: (2019)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
por: Sehr, Tony, et al.
Publicado: (2020)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease
por: Thomas, Katja, et al.
Publicado: (2014)

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study
por: Linker, Ralf A., et al.
Publicado: (2016)

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations
por: Ayzenberg, Ilya, et al.
Publicado: (2016)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation
por: Thomas, Katja, et al.
Publicado: (2017)

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
por: Alsop, Jonathan, et al.
Publicado: (2017)

Electrocardiographic imaging for cardiac arrhythmias and resynchronization therapy
por: Pereira, Helder, et al.
Publicado: (2020)

Electrocardiographic patch devices and contemporary wireless cardiac monitoring
por: Fung, Erik, et al.
Publicado: (2015)

Electrocardiographic Parameters as Predictors of Response to Cardiac Resynchronization Therapy
por: Poposka, Lidija, et al.
Publicado: (2018)

Cardiac repolarization during fingolimod treatment in patients with relapsing–remitting multiple sclerosis
por: Laiho, Aapo, et al.
Publicado: (2018)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Update on the Cardiac Safety of Moxifloxacin
por: Haverkamp, Wilhelm, et al.
Publicado: (2012)

Electrocardiographic disturbances after cardiac surgery in patients with coronary disease
por: Guimarães, HP, et al.
Publicado: (2005)

Comparison of Echocardiographic and Electrocardiographic Mapping for Cardiac Resynchronisation Therapy Optimisation
por: Pereira, Helder, et al.
Publicado: (2019)

The role of electrocardiographic imaging in patient selection for cardiac resynchronization therapy
por: Abu-Alrub, Saer, et al.
Publicado: (2021)

Analysing electrocardiographic traits and predicting cardiac risk in UK biobank
por: Ramírez, Julia, et al.
Publicado: (2021)

Electrocardiographic manifestations of COVID-19: Effect on cardiac activation and repolarization
por: Thakore, Avni, et al.
Publicado: (2021)

Machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis
por: Schrutka, Lore, et al.
Publicado: (2022)

Association of Number of Live Births With Electrocardiographic and Cardiac Structural Changes
por: Harris, Elizabeth, et al.
Publicado: (2022)

Cardiac Memory T-wave Inversions Noted with Ventricular Pacing: A Possible Electrocardiographic Marker of Appropriate Conduction System Pacing
por: Cossú, Sergio F.
Publicado: (2023)

Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic
por: Brown, Brandon, et al.
Publicado: (2019)

PTB-XL+, a comprehensive electrocardiographic feature dataset
por: Strodthoff, Nils, et al.
Publicado: (2023)

Epilepsy-induced electrocardiographic alterations following cardiac ischemia and reperfusion in rats
por: Tavares, J.G.P., et al.
Publicado: (2015)

Cardiac electrophysiological adaptations in the equine athlete—Restitution analysis of electrocardiographic features
por: Li, Mengye, et al.
Publicado: (2018)

The effect of type 2 diabetes on electrocardiographic markers of significant cardiac events
por: Kuzu, Fatih
Publicado: (2018)

Erratum to “Comparison of Echocardiographic and Electrocardiographic Mapping for Cardiac Resynchronisation Therapy Optimisation”
por: Pereira, Helder, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fcpno1952sup7nqmremm26su9q